The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
about
Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.The tumor microenvironment and strategies to improve drug distributionPre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinomaTen years of progress in radiation oncologyPulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors.Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.Targeting CD137 enhances the efficacy of cetuximab.Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imagingThe hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid TumorsTime-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies.Odyssey of a cancer nanoparticle: from injection site to site of action.Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor ModelsDose dependence of intratumoral perivascular distribution of monoclonal antibodies.Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth.Targeted drug delivery for cancer therapy: the other side of antibodies.Strategies to increase drug penetration in solid tumors.Trends in cancer-targeted antibody-drug conjugates.Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.Overcoming physical barriers in cancer therapy.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1.Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer.A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patientsDevelopment of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs.Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay.Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment
P2860
Q27329648-01A8084D-62E8-40DC-B5D4-CCC26F114FFAQ28384148-1A7D0159-34FE-4C14-87F7-02B200768D5CQ28481572-D01F87EF-C619-4812-B02C-E7013C042763Q30318247-8D64E08E-121C-4CA9-9C39-12F1CE003F2BQ30426788-CE351020-9915-4BFB-AD0E-154910A1C662Q33850467-219AE4A3-3168-488F-9C47-146255E87499Q33872482-469F4242-C54A-4CF5-B11A-354EF9CE1D7BQ33912075-E6004244-7775-49DC-A578-D5664FD996AEQ34502985-B752A870-2D45-4F4E-A83E-FEABBCC696F7Q35649008-6B0ABA26-D74B-4766-BDCE-BC036EC4A094Q35651085-B6F9C2A4-7E7A-4D72-863C-B4060EC68618Q35868868-079E6811-E508-4489-92FB-A695C5677D22Q36216452-C4E3BBAE-32B1-4493-8193-405B7683FF53Q36459196-ED46F656-8C37-429E-B2D6-F109C75F29F9Q36825407-B4067BC8-3567-49F7-A7EB-870AA159B3CEQ37677220-57A5BD20-5322-44C4-9EE8-CE676B795A5FQ37689046-F9ED5280-A011-40B9-A738-3306D22D881CQ38058816-747C77FD-5485-4B26-9D1B-8F332AAE7037Q38125197-058DC8E5-7C5D-43CE-80EC-E19222787AE5Q38162127-C432DD92-8086-42D5-9C16-EB8D268C4CDCQ38204975-2057930C-6E91-460B-8170-A0DFFC4F34A5Q38318962-70223C64-512B-49B9-B3DB-4C776B10337AQ38808823-A25CDB6A-B12C-41BD-9556-233DE7824FEBQ41573532-8495B3E0-7C16-4A72-8CC5-E694F7E474FCQ41849636-E1D199DC-37F1-4101-ABB4-612C09D42072Q41925374-2C5D1850-006D-4B8C-B0E9-75FCD2B288AFQ41940445-8584FAD2-B259-418C-A1C8-2D13F1DF6C48Q47100953-96F96818-FBD3-4CC5-9B6D-19B654EFBA70Q47735319-2BC38958-CCE4-45AF-9335-B3E3322C98E1Q51749302-3B6A62E0-407A-44C6-AE55-09BA1F13412CQ55100565-ECB41BF2-20CA-4B0E-AA21-B98A55F12716Q55439903-13648884-02D9-4461-AB5E-CC8B4A74AE1BQ58698483-CBA53308-6BD7-4A9F-9E65-40B6DD7A3156
P2860
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The distribution of the therap ...... rastuzumab within solid tumors
@ast
The distribution of the therap ...... rastuzumab within solid tumors
@en
type
label
The distribution of the therap ...... rastuzumab within solid tumors
@ast
The distribution of the therap ...... rastuzumab within solid tumors
@en
prefLabel
The distribution of the therap ...... rastuzumab within solid tumors
@ast
The distribution of the therap ...... rastuzumab within solid tumors
@en
P2860
P356
P1433
P1476
The distribution of the therap ...... rastuzumab within solid tumors
@en
P2093
Carol M Lee
Ian F Tannock
P2860
P2888
P356
10.1186/1471-2407-10-255
P407
P577
2010-06-03T00:00:00Z
P5875
P6179
1013540131